New priority program opens up exclusive opportunities for collaborative research on transformative clinical potential of DNAe's flagship tests and to gain preview of breakthrough LiDia-SEQ™ platform ...
LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced the initiation of an Expanded Access Program (EAP) for molgramostim, ...
Madrid, January 27 th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist Clinical Research Organization (CRO) have today announced the launch of an Expanded Access Program (EAP) for ...
Clinigen launches ‘What is Possible?’ campaign to accelerate access to medicines on Rare Disease Day
With over 7,000 rare diseases that impact over 300 million people globally, just 5% of rare diseases have a licensed treatment* LONDON, UK, 29 February 2024 – Clinigen, the global pharmaceutical ...
NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time ...
When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a new layer of information,” specifically ...
Pharma looks to take advantage of expanded access programs across Asia-Pacific region. While Asia represents an increasingly important market for innovative therapies, it is not an easy one to crack.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback